Identification of a broad-Spectrum azasordarin with improved pharmacokinetic properties
Michael H. Serrano‐Wu(Broad Institute), Balu Balasubramanian(Bristol-Myers Squibb (United States)), Claude Quesnelle(Bristol-Myers Squibb (United States)), Terry M. Stickle(Bristol-Myers Squibb (United States)), Alicia Regueiro‐Ren(Bristol-Myers Squibb (United States)), Zheng Yang(Renmin Hospital of Wuhan University), Tina M. Carroll(Bristol-Myers Squibb (United States)), Minghao Zheng(The University of Western Australia), Patrice Gill(Bristol-Myers Squibb (Canada)), Marco Dodier(Bristol-Myers Squibb (Canada)), Dedong Wu(Bristol-Myers Squibb (United States)), Denis R. St. Laurent(Bristol-Myers Squibb (United States)), Hyekyung Yang(Bristol-Myers Squibb (United States)), Mary Zoeckler(Bristol-Myers Squibb (United States)), Charles E. Mazzucco(Bristol-Myers Squibb (United States)), Qi Gao, Dolatrai M. Vyas(Bristol-Myers Squibb (United States)), Anne Marinier(Institute for Research in Immunology and Cancer)
Cited by 12
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
|Antimicrobial Agents and Chemotherapy|2006|239
Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole
|Oncogene|2006|211
Identification of Hepatitis C Virus NS5A Inhibitors
|Journal of Virology|2009|196